<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vildagliptin is a potent and selective oral dipeptidyl peptidase-4 inhibitor that improves glycaemic control in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) by increasing both alpha- and beta-cell responsiveness to <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The efficacy, tolerability and safety of the combination of vildagliptin and <z:chebi fb="0" ids="6801">metformin</z:chebi> in the treatment of T2DM have been established in numerous trials in the extensive vildagliptin clinical programme </plain></SENT>
<SENT sid="2" pm="."><plain>As add-on therapy in patients with inadequate glycaemic control on <z:chebi fb="0" ids="6801">metformin</z:chebi>, vildagliptin produces clinically significant reductions in glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, is well tolerated, and is associated with absence of <z:mp ids='MP_0005456'>weight gain</z:mp> and minimal risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with thiazolidinedione add-on treatment, vildagliptin is associated with similar significant reductions in HbA1c without the <z:mp ids='MP_0005456'>weight gain</z:mp> seen with the former </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> add-on treatment, vildagliptin is associated with similar efficacy in controlling glycaemia but absence of <z:mp ids='MP_0005456'>weight gain</z:mp> and a markedly lower risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In drug-naive patients, single-tablet combinations of vildagliptin/<z:chebi fb="0" ids="6801">metformin</z:chebi> 50/500 and 50/1000 mg bid produced significantly greater reductions in HbA1c than monotherapy with either agent and were well tolerated, with no <z:mp ids='MP_0005456'>weight gain</z:mp> and minimal risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The combination of vildagliptin and <z:chebi fb="0" ids="6801">metformin</z:chebi> poses numerous advantages in the treatment of T2DM </plain></SENT>
</text></document>